Omalizumab + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasal Polyps
Conditions
Nasal Polyps, Chronic Rhinosinusitis
Trial Timeline
Nov 21, 2017 → Mar 7, 2019
NCT ID
NCT03280537About Omalizumab + Placebo
Omalizumab + Placebo is a phase 3 stage product being developed by Roche for Nasal Polyps. The current trial status is completed. This product is registered under clinical trial identifier NCT03280537. Target conditions include Nasal Polyps, Chronic Rhinosinusitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03478930 | Phase 3 | Completed |
| NCT03280537 | Phase 3 | Completed |
| NCT03280550 | Phase 3 | Completed |
Competing Products
20 competing products in Nasal Polyps